基于核磁共振1H谱的乳腺纤维腺瘤与乳腺浸润性导管癌血清代谢组学比较研究

目的 分析乳腺纤维腺瘤患者及乳腺浸润性导管癌患者在血清代谢组学上的差异，探讨术前通过代谢特征来辨别良恶性肿瘤的可能性。方法 收集经临床确诊的乳腺纤维腺瘤和乳腺浸润性导管癌患者血清各8例，通过核磁共振¹H谱（¹HNMR）技术检测其血清代谢组特征，分别采用主成分分析（PCA）和正交偏最小二乘判别法 （OPLS-DA）分析乳腺纤维腺瘤与乳腺浸润性导管癌之间的代谢差异。结果 PCA和OPLS-DA分析显示乳腺纤维腺瘤患者和乳腺浸润性导管癌患者的血清代谢特征存在明显差异。与乳腺纤维腺瘤患者相比，浸润性导管癌患者血清中脂质、乳酸盐、磷脂酰胆碱/甘油磷脂酰胆碱的含量升高，而谷氨酰胺、牛磺酸、肌酸和葡萄糖含量降低。结论 乳腺纤维腺瘤患者与乳腺浸润性导管癌患者在血清代谢水平上具有明显差异，这些具有明显变化的代谢物可作为潜在血清代谢标记物，为临床区分良恶性肿瘤提供参考。

The 1H NMR-based serum metabonomics study of breast fibroadenoma and breast invasive ductal carcinoma patients

Objective To explore the serum metabonomic difference between breast fibroadenoma patients and breast invasive ductal carcinoma patients using nuclear magnetic resonance ¹H (¹HNMR) spectroscopy, and to discuss the possibility of using it for differentiation of benign and malignant breast tumor before operation. Methods Eight clinically diagnosed breast fibroadenoma patients and 8 breast invasive ductal carcinoma patients were recruited and their sera were collected; ¹HNMR was used to obtain the metabonomic characteristics. The data were processed using Simca-P software and analyzed with principle component analysis(PCA) and orthogonal signal correction partial least squares discrimination analysis(OPLS-DA). Results PCA and OPLS-DA analyses showed great differences in serum metabonomics between breast fibroadenoma and breast invasive ductal carcinoma. Compared with breast fibroadenoma patients, patients with invasive ductal carcinoma had higher levels of lipid, lactate and phosphocholine lglycerolphospholine, and lower levels of glutamine, taurine, creatine, and glucose. Conclusion Distinct difference exists in serum metabonomic profiles between breast adenoma patients and breast invasive ductal carcinoma patients, which may serve as the potential biomarkers to differentiate malignant tumors from benign ones in clinic.